Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer ’s disease in the context of a structured 5-phase biomarker development framework

ConclusionCurrent literature provides partial evidence for clinical utility of [18F]flortaucipir PET. The aims for phases 1 and 2 were mostly achieved. Phase 3 studies are currently ongoing. Future studies including representative MCI populations and a focus on healthcare outcomes are required to establish full maturity of phases 4 and 5.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research